Skip to main content
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2023 Jan 2;25(1):277–281. doi: 10.1021/acs.orglett.2c04145

Site-Selective Functionalization of Unactivated Allylic C–H Bonds via Direct Deprotonation with KTMP: Application to the Formal Total Synthesis of (+)-Artemisinin from Amorphadiene

Nicholas A Clanton , Nicolas A Wilson , Eliezer Ortiz , Shawn T Blumberg , Doug E Frantz ‡,*
PMCID: PMC9841608  PMID: 36592432

Abstract

graphic file with name ol2c04145_0005.jpg

The site-selective functionalization of unactivated allylic C–H bonds via direct deprotonation using KTMP is described. The conversion of amorphadiene to artemisinic alcohol via a simple, highly regioselective deprotonation over 4 other possible allylic sites is shown with further extrapolation to the first large-scale telescoped chemical synthesis of artemisinic acid from amorphadiene. Finally, application of the method for the successful site-selective functionalization of unactivated allylic C–H bonds in other terpene-based natural products is also highlighted.


The latest World Malaria Report from the World Health Organization (WHO) estimated 241 million cases of malaria and 627,000 deaths in 2020.1 Unfortunately, these numbers represent a significant increase compared to 2019 and were exacerbated by disruptions in prevention, diagnosis, and treatment of malaria due to the ongoing COVID-19 pandemic. Further disruptions in global supply chains continue to negatively impact the production of antimalarials and ultimately contribute to reduced gains in malaria-endemic countries.

In the battle against malaria, artemisinin-based combined therapies (ACTs) remain as the first-line arsenal for the treatment of uncomplicated disease caused by P. falciparum and, in select cases, by P. vivax. Global demand for ACTs continues to grow, up to 218 metric tons (MT) in 2021;2 however, meeting this demand has been hampered not only due to COVID-19 but the long-term supply issues of artemisinin (1) itself. During the past 20 years, the world’s supply and cost of artemisinin has been notably erratic. Extraction from Artemisia annua L. continues to be the major source of this API (100–120 MT/year), yet sustainable supplies are dependent on varying market dynamics, climate change, geographical location, and geopolitical pressures. The remaining gap in artemisinin stock is supplemented by semisynthetic industrial approaches (50–60 MT/year) that rely on the biosynthetic production of artemisinic acid (AA, 5) via fermentation of sugar in titers of ∼25 g/L using genetically engineered strains of Saccharomyces cerevisiae (brewer’s yeast).3,4 Significant effort has since been put forth to optimize the chemical transformation of AA to artemisinin. Despite these elegant strategies, the cost of semisynthetic approaches (350–400 $/kg) still do not compete with the current price of artemisinin obtained by extraction (250 $/kg).

Interestingly, the initial fermentation step used to produce amorph-4,11-diene (amorphadiene, AD, 2) is capable of producing titers that are up to 5 times higher (∼120 g/L) than was obtainable for AA.5 Thus, realizing that AD could serve as a more attractive precursor to develop a semisynthetic route to artemisinin, Amyris developed two approaches to oxidize AD via either selective hydroboration/oxidation or epoxidation of the exocyclic double bond. However, both of these routes were abandoned and deemed too costly at the time.6 Renewed efforts to utilize AD involved a 6-step synthetic sequence beginning with selective epoxidation of the endocyclic double bond allowing for subsequent manipulation of the exocyclic olefin that ultimately culminated with a Li-metal mediated reductive removal of the epoxide to provide dihydroartemisinic acid (DHAA).7 However, the implementation of this route on production scale, to the best of our knowledge, has yet to occur.

Biomimetic approaches that target intermediates along biosynthetic pathways are proven strategies for the total synthesis of natural products. From this perspective, the development of a direct chemical conversion of AD to artemisinic alcohol (3), the next intermediate on the biosynthetic pathway to artemisinin, could provide significant advantages over previous semisynthetic approaches. In turn, this strategy would complement existing total syntheses of artemisinin that start from commodity raw materials, most notable of these being the graceful approach developed by Cook.8 Captivated by the recent success of the Cossy and Amara groups on the functionalization of AD,911 in particular the Pd-catalyzed regioselective oxidation of AD,12 we embarked on our own efforts to identify a robust and efficient approach for the direct conversion of AD to artemisinic alcohol as a biomimetic formal total synthesis to artemisinin (Scheme 1).

Scheme 1. (a) Engineered Biosynthesis toward the Industrial Semisynthesis of (+)-Artemisinin; (b) Pd-Catalyzed Regioselective Oxidation of Amorphadiene (AD) by Cossy and Amara; (c) Our Approach: Site-Selective C–H functionalization via Deprotonation/Oxidation of AD to Artemisinic Alcohol.

Scheme 1

Direct chemoselective and site-selective C–H functionalization of complex naturally occurring sesquiterpenes, such as AD, remains a formidable challenge for synthetic organic chemists. From this perspective, in an age where catalytic C–H functionalizations are making great strides, simple and efficient stoichiometric functionalizations can sometimes be overlooked. For example, regioselective stoichiometric deprotonations have been a proven strategy for the functionalization of unsaturated hydrocarbons, including terpenes, since the 1970s. The landmark study by Crawford on the direct metalation of limonene using n-BuLi-TMEDA catalyzed a series of subsequent investigations by others in the field.13 In the 1980s Schlosser’s “superbase” system14,15 that combined n-BuLi with KOtBu (LICKOR) gained notoriety and was demonstrated in the selective allylic deprotonation of simple olefins and terpenoids.16 However, the application of these deprotonation strategies to more complex sesquiterpenes, including AD, has yet to be demonstrated.

A selected subset of our initial exploratory reactions for the selective deprotonation of AD followed by borylation/oxidation is presented in Table 1 (see Supporting Information for more details). Preliminary proof of concept was realized using n-BuLi-TMEDA in hexanes; conditions previously shown to metalate limonene.13 However, conversion of AD to 3 was low with concomitant formation of isomeric allylic alcohol 6 (Table 1, entries 1 and 3). Even lower conversion was realized using a s-BuLi-TMEDA combination (Table 1, entry 2). Significant conversion was not realized until the ternary combination of n-BuLi, KOtBu, and 2,2,6,6-tetramethylpiperidine (TMP) in THF was employed (Table 1, entry 7). Additional optimization of this result using 2 equiv of each reagent at −78 °C provided high conversion of AD (89%), exceptional site-selectivity (>20:1), and an excellent isolated yield of 3 (81%) (Table 1, entry 9). It is important to note that proven methods for allylic deprotonations of terpene-based natural products using alkyl potassium superbases (e.g., Schlosser’s LICKOR conditions) completely failed to deprotonate AMD (Table 1, entry 5). Furthermore, reactions without KOtBu (generating LiTMP) or n-BuLi alone, failed to provide any measurable conversion by 1H NMR (Table 1, entries 4 and 6). These data taken together provide supporting evidence that KTMP is required to achieve high conversion and regioselectivity for the deprotonation of AMD. As far as we are aware, this represents the first example of a regioselective allylic deprotonation using KTMP.17 To address the challenges of using cryogenic temperatures on an industrial scale, we explored reaction conditions using KTMP in hydrocarbon solvents where increased thermal stability is known over ethereal solvents.18 We were pleased to realize promising conversion (68%) and site-selectivity (3:1) using heptane as the solvent at room temperature using 3 equiv of KTMP (Table 1, entry 12). Alternatively, the use of continuous flow conditions could also be employed, as demonstrated by Knochel.19

Table 1. Initial Exploration of the Regioselective Deprotonation/Oxidation of Amorphadiene.

graphic file with name ol2c04145_0004.jpg

entrya R-Li (equiv) additive (equiv) KOtBu (equiv) solvent temp (°C) time (h) conversion of AD (%)b yield (%)c 3:6d
1 n-BuLi (0.67) TMEDA (0.67) none hexanes 0 16 35 ND 3:1
2 s-BuLi (0.67) TMEDA (0.67) none cyclohexane 0 16 6 ND 5:1
3 n-BuLi (1.0) none 1.0 hexanes 0 24 25 ND 2:1
4 n-BuLi (1.0) none none THF –78 1 <5 ND ND
5 n-BuLi (1.2) none 1.2 THF –78 1 <5 ND ND
6 n-BuLi (1.2) TMP (1.2) none THF –78 1 <5 ND ND
7 n-BuLi (1.2) TMP (1.2) 1.2 THF –78 1 72 60 >20:1
8 n-BuLi (1.5) TMP (1.5) 1.5 THF –78 1 78 72 >20:1
9 n-BuLi (2.0) TMP (2.0) 2.0 THF –78 1 89 81 >20:1
10 n-BuLi (2.0) TMP (2.0) 2.0 THF –40 1 <5 ND ND
11 n-BuLi (2.0) TMP (2.0) 2.0 THF –25 1 <5 ND ND
12 n-BuLi (3.0) TMP (3.0) 3.0 heptane 23 24 68 39 3:1
a

All reactions performed on a 0.5 mmol scale of AD at 0.1 M concentration with 1 equiv of B(OiPr)3 and 2 equiv of H2O2 relative to n-BuLi.

b

Determined via 1H NMR analysis of crude reaction mixtures by comparing the relative amounts of AD to 3 and 6 combined.

c

Isolated yields.

d

Ratios determined on crude reaction mixtures by 1H NMR.

With a highly regioselective and robust deprotonation/oxidation of AD in hand, we turned our attention to developing a process to convert AD to artemisinic acid (5) without isolation or purification of any intermediates. After minimal rounds of optimization, we have identified a two-step/one-pot oxidation sequence using crude artemisinic alcohol (3) obtained from the regioselective deprotonation to provide 5 in high isolated yield on a 50 mmol scale (Scheme 2). Regioselective deprotonation/oxidation of AD using KTMP as described above provided artemisinic alcohol 3 in 86% conversion with 24:1 artemisinic alcohol 3 in 86% conversion with 24:1 regioselectivity as determined by 1H NMR analysis. Oxidation of crude 3 to artemisinic aldehyde 4 was realized via a Cu-catalyzed oxidation using O2 as the stoichiometric oxidant in >99% conversion as determined by 1H NMR after 1 h. Subsequent conversion of 4 to 5 was achieved in 71% HPLC assay yield from AD via a Pinnick oxidation using 2-methyl-2-butene (15 equiv) as the scavenger for the HOCl byproduct. Isolation via direct crystallization from acetonitrile/H2O provided 5 in 58% overall yield from AD resulting in an average yield of 83% for each of the three steps. Downstream industrial conversion of artemisinic acid (AA) to (+)-artemisinin is a highly optimized route capable of producing 50–60 tons/year in ∼55% overall yield, thus completing the formal total synthesis route from AD.20

Scheme 2. Through Process for the Conversion of AD to AA on 50 mmol Scale.

Scheme 2

Intrigued by the highly site-selective deprotonation of AD enabled by KTMP, we were curious if this method could be used to selectively functionalize unactivated allylic C–H bonds in other terpene-related natural products. A summary of our preliminary efforts is provided in Scheme 3 (see Supporting Information for experimental details on each example). For example, the robustness of the method allows for the direct site-selective C–H functionalization of (+)-limonene contained in naturally occurring orange oil (∼$1,650/55 gallons) to provide (+)-limone-10-ol (7) in 77% yield. The related cyclic monoterpene α-phellandrene is selectively functionalized at the exocyclic allylic position to provide cuminyl alcohol (8) in 48% yield after unavoidable aromatization during workup. Selective deprotonation/oxidation of (−)-perillyl alcohol provides (−)-10-hydroxyperillyl alcohol (9) in 70% yield that, as far as we are aware, has only been achievable using biotransformation approaches in the past.21 Likewise, the regioselective functionalization of (+)-β-citronellene yields (+)-(Z)-allylic alcohol 10 in (86:14, Z:E); a functionalized enantiopure monoterpene that has remained elusive until now. In a similar fashion, the site-selective deprotonation/oxidation of (±)-β-citronellol provides direct access to (±)-(Z)-8-hydroxycitronellol (11, 91% yield, 84:16, Z:E), a precursor to an HIV protease inhibitor, that previously required 5 steps to synthesize from (±)-citronellal.22 The Z-selectivity obtained for both 10 and 11 is consistent with the thermodynamic preference for allylic potassium species to exist in the endo-Z conformation.23 KTMP can also be used to selectively hydroxylate (−)-isopulegol to provide diol 12 in 93% isolated yield. The site-selective oxidation of natural grade (+)-valencene (74% purity, $780/kg) to provide valencen-13-ol (13) in 77% yield represents the most direct and highest yielding method to this known tick repellent.24 Finally, we were elated to realize the site-selective C–H functionalization of cannabidiol (CBD) to provide 10-hydroxy-CBD (14) in an impressive 52% isolated yield. Previous SAR studies on CBD at the 10-position have demonstrated these derivatives can block the antinociceptive activity of Δ9-THC.25

Scheme 3. Site-Selective C–H Functionalization of Terpene-Based Natural Products via KTMP Deprotonation/Oxidation.

Scheme 3

In conclusion, we have discovered and developed a direct allylic C–H functionalization of amorphadiene (AD) to artemisinic alcohol via a highly regioselective deprotonation. Critical to the success of this reaction is the use of KTMP as the preferred base that demonstrates superior regioselectivity for deprotonation at C12 over 4 other possible allylic sites in AD. Extrapolation of this method to the first telescoped chemical synthesis of artemisinic acid from amorphadiene with implications for the large-scale semisynthetic production of artemisinin is also demonstrated on a 50 mmol scale. Finally, extension of this method to the site-selective allylic C–H functionalization of other terpene-based natural products was also explored.

Acknowledgments

D.E.F. and S.T.B. would like to thank Prof. Karl A. Scheidt for helpful discussions during manuscript preparation. S.T.B. would like to thank the Bill and Melinda Gates Foundation (OPP1189441) for supporting the development of an alternative synthesis of amorphadiene that was subsequently used in this research. D.E.F. would also like to thank the Max and Minnie Tomerlin Voelcker Fund for unrestricted funds to our laboratories.

Data Availability Statement

The data underlying this study are available in the published article and its online Supporting Information.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.orglett.2c04145.

  • Full experimental details and characterization, 1H and 13C NMR spectra of all final products (PDF)

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

This work was funded by the CONNECT Program through the Office of the Vice President for Research, Economic Development, and Knowledge Enterprise at UTSA and Southwest Research Institute. The UTSA NMR and X-ray facilities are supported by the NSF (CHE-1625963 and CHE-1920057).

The authors declare the following competing financial interest(s): All authors are listed as co-inventors on a provisional patent application related to this work.

Supplementary Material

ol2c04145_si_001.pdf (4.9MB, pdf)

References

  1. World Malaria Report . https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021 (accessed 2022 February 4, 2022).
  2. Global Malaria Diagnostic and Artemisinin Treatment Commodities Demand Forecast 2017–2021. 2018. https://unitaid.org/assets/Global-malaria-diagnostic-and-artemisinin-treatment-commodities-demand-forecast-2017-%E2%80%93-2021-Report-May-2018.pdf (accessed 2022 February 3, 2022).
  3. Paddon C. J.; Westfall P. J.; Pitera D. J.; Benjamin K.; Fisher K.; McPhee D.; Leavell M. D.; Tai A.; Main A.; Eng D.; Polichuk D. R.; Teoh K. H.; Reed D. W.; Treynor T.; Lenihan J.; Fleck M.; Bajad S.; Dang G.; Dengrove D.; Diola D.; Dorin G.; Ellens K. W.; Fickes S.; Galazzo J.; Gaucher S. P.; Geistlinger T.; Henry R.; Hepp M.; Horning T.; Iqbal T.; Jiang H.; Kizer L.; Lieu B.; Melis D.; Moss N.; Regentin R.; Secrest S.; Tsuruta H.; Vazquez R.; Westblade L. F.; Xu L.; Yu M.; Zhang Y.; Zhao L.; Lievense J.; Covello P. S.; Keasling J. D.; Reiling K. K.; Renninger N. S.; Newman J. D. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 2013, 496 (7446), 528–532. 10.1038/nature12051. [DOI] [PubMed] [Google Scholar]
  4. Ro D. K.; Paradise E. M.; Ouellet M.; Fisher K. J.; Newman K. L.; Ndungu J. M.; Ho K. A.; Eachus R. A.; Ham T. S.; Kirby J.; Chang M. C.; Withers S. T.; Shiba Y.; Sarpong R.; Keasling J. D. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 2006, 440 (7086), 940–943. 10.1038/nature04640. [DOI] [PubMed] [Google Scholar]
  5. Westfall P. J.; Pitera D. J.; Lenihan J. R.; Eng D.; Woolard F. X.; Regentin R.; Horning T.; Tsuruta H.; Melis D. J.; Owens A.; Fickes S.; Diola D.; Benjamin K. R.; Keasling J. D.; Leavell M. D.; McPhee D. J.; Renninger N. S.; Newman J. D.; Paddon C. J. Production of amorphadiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin. Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (3), E111–118. 10.1073/pnas.1110740109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Reiling K. K.; Renninger N.; McPhee D. J.; Fisher K. J.; Ockey D. A.. Conversion of amorpha-4,11,-diene to artemisinin and artemisinin precursors. US20060270863A1.
  7. Singh D.; McPhee D.; Paddon C. J.; Cherry J.; Maurya G.; Mahale G.; Patel Y.; Kumar N.; Singh S.; Sharma B.; Kushwaha L.; Singh S.; Kumar A. Amalgamation of Synthetic Biology and Chemistry for High-Throughput Nonconventional Synthesis of the Antimalarial Drug Artemisinin. Org. Process Res. Dev. 2017, 21 (4), 551–558. 10.1021/acs.oprd.6b00414. [DOI] [Google Scholar]
  8. Zhu C.; Cook S. P. A concise synthesis of (+)-artemisinin. J. Am. Chem. Soc. 2012, 134 (33), 13577–13579. 10.1021/ja3061479. [DOI] [PubMed] [Google Scholar]
  9. Gomez Fernandez M. A.; Nascimento de Oliveira M.; Zanetti A.; Schwertz G.; Cossy J.; Amara Z. Photochemical Hydrothiolation of Amorphadiene and Formal Synthesis of Artemisinin via a Pummerer Rearrangement. Org. Lett. 2021, 23 (15), 5593–5598. 10.1021/acs.orglett.1c00636. [DOI] [PubMed] [Google Scholar]
  10. Zanetti A.; Chaumont-Olive P.; Schwertz G.; Nascimento de Oliveira M.; Gomez Fernandez M. A.; Amara Z.; Cossy J. Crystallization-Induced Diastereoisomer Transformation of Dihydroartemisinic Aldehyde with the Betti Base. Org. Process Res. Dev. 2020, 24 (5), 850–855. 10.1021/acs.oprd.9b00481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schwertz G.; Zanetti A.; de Oliveira M. N.; Fernandez M. A. G.; Amara Z.; Cossy J. Chemo- and Diastereoselective Hydrosilylation of Amorphadiene toward the Synthesis of Artemisinin. J. Org. Chem. 2020, 85 (15), 9607–9613. 10.1021/acs.joc.0c00617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Zanetti A.; Schwertz G.; de Oliveira M. N.; Gomez Fernandez M. A.; Amara Z.; Cossy J. Palladium-Catalyzed Regioselective Allylic Oxidation of Amorphadiene, a Precursor of Artemisinin. J. Org. Chem. 2021, 86 (11), 7603–7608. 10.1021/acs.joc.1c00653. [DOI] [PubMed] [Google Scholar]
  13. Crawford R. J.; Erman W. F.; Broaddus C. D. Metalation of limonene. Novel method for the synthesis of bisabolane sesquiterpenes. J. Am. Chem. Soc. 1972, 94 (12), 4298–4306. 10.1021/ja00767a044. [DOI] [Google Scholar]
  14. Schlosser M. Superbases for organic synthesis. Pure Appl. Chem. 1988, 60 (11), 1627–1634. 10.1351/pac198860111627. [DOI] [Google Scholar]
  15. Schlosser M.; Strunk S. The “super-basic” butyllithium/potassium tert-butoxide mixture and other lickor-reagents. Tetrahedron Lett. 1984, 25 (7), 741–744. 10.1016/S0040-4039(01)80014-9. [DOI] [Google Scholar]
  16. Schlosser M. Superbases for organic synthesis. Pure Appl. Chem. 1988, 60 (11), 1627–1634. 10.1351/pac198860111627. [DOI] [Google Scholar]
  17. Klusener P. A. A.; Tip L.; Brandsma L. On the direct metalation of isoprene. Tetrahedron 1991, 47 (10–11), 2041–2064. 10.1016/S0040-4020(01)96114-9. [DOI] [Google Scholar]
  18. Armstrong D. R.; Graham D. V.; Kennedy A. R.; Mulvey R. E.; O’Hara C. T. A structural and computational study of synthetically important alkali-metal/tetramethylpiperidide (TMP) amine solvates. Chemistry 2008, 14 (26), 8025–8034. 10.1002/chem.200800158. [DOI] [PubMed] [Google Scholar]
  19. Harenberg J. H.; Weidmann N.; Knochel P. Preparation of Functionalized Aryl, Heteroaryl, and Benzylic Potassium Organometallics Using Potassium Diisopropylamide in Continuous Flow. Angew. Chem., Int. Ed. Engl. 2020, 59 (30), 12321–12325. 10.1002/anie.202003392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Amara Z.; Bellamy J. F.; Horvath R.; Miller S. J.; Beeby A.; Burgard A.; Rossen K.; Poliakoff M.; George M. W. Applying green chemistry to the photochemical route to artemisinin. Nat. Chem. 2015, 7 (6), 489–495. 10.1038/nchem.2261. [DOI] [PubMed] [Google Scholar]
  21. Hamada H.; Tanaka T.; Furuya T.; Takahata H.; Nemoto H. Hydroxylation of benzylic and allylic sites by plant cultured suspension cells. Tetrahedron Lett. 2001, 42 (5), 909–911. 10.1016/S0040-4039(00)02132-8. [DOI] [Google Scholar]
  22. Zhao X. Z.; Tu Y. Q.; Peng L.; Li X. Q.; Jia Y. X. Synthetic studies of the HIV-1 protease inhibitive didemnaketals: stereocontrolled synthesis of an ester side chain. Tetrahedron Lett. 2004, 45 (19), 3713–3716. 10.1016/j.tetlet.2004.03.103. [DOI] [Google Scholar]
  23. Schlosser M.; Hartmann J. 2-Alkenyl anions and their surprising endo preference. Facile and extreme stereocontrol over carbon-carbon linking reactions with organometallics of the allyl type. J. Am. Chem. Soc. 1976, 98 (15), 4674–4676. 10.1021/ja00431a070. [DOI] [Google Scholar]
  24. Dietrich G.; Dolan M. C.; Peralta-Cruz J.; Schmidt J.; Piesman J.; Eisen R. J.; Karchesy J. J. Repellent Activity of Fractioned Compounds fromChamaecyparis nootkatensisEssential Oil Against NymphalIxodes scapularis (Acari: Ixodidae). J. Med. Ent. 2006, 43 (5), 957–961. 10.1093/jmedent/43.5.957. [DOI] [PubMed] [Google Scholar]
  25. Jorapur V. S.; Khalil Z. H.; Duffley R. P.; Razdan R. K.; Martin B. R.; Harris L. S.; Dewey W. L. Hashish: synthesis and central nervous system activity of some novel analogues of cannabidiol and oxepin derivatives of delta 9-tetrahydrocannabinol. J. Med. Chem. 1985, 28 (6), 783–787. 10.1021/jm00383a016. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ol2c04145_si_001.pdf (4.9MB, pdf)

Data Availability Statement

The data underlying this study are available in the published article and its online Supporting Information.


Articles from Organic Letters are provided here courtesy of American Chemical Society

RESOURCES